101140 — InBioGen Co Income Statement

0.000.00%

Last trade - 00:00

IndustrialsHighly SpeculativeSmall CapNeutral

Annual income statement for InBioGen Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS/A	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	10,218	10,481	10,420	6,241	7,041
Cost of Revenue
Gross Profit	812	1,959	2,359	1,331	660
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	40,160	22,384	22,938	86,117	14,127
Operating Profit	-29,942	-11,903	-12,519	-79,876	-7,086
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-45,218	111,064	-136,371	11,859	16,122
Provision for Income Taxes
Net Income After Taxes	-45,078	94,125	-119,418	11,859	16,122
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-45,078	94,125	-119,687	11,344	16,122
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-45,078	94,125	-119,687	11,344	16,122
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-14,032	32,664	-42,245	10,064	1,731
Dividends per Share